Browsing "Infectious Diseases" by Keyword : COVID-19
Showing results 8 to 23 of 23
| Pub Year | | Title | Author(s) |
| 2024 | | Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy | 김영롱, 정근옥, 허중연 |
| 2023 | | Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection | 허중연 |
| 2022 | | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study | 허중연 |
| 2023 | | Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | 김은진, 허중연 |
| 2023 | | Impact of COVID-19 pandemic on healthcare-associated infections at intensive care units in South Korea: data from the Korean National Healthcare-Associated Infections Surveillance System (KONIS) | 김은진 |
| 2021 | | Implementation of the COVID-19 vulnerability index across an international network of health care data sets: Collaborative external validation study | 박래웅, 최영화 |
| 2020 | | Interim Guidelines on Antiviral Therapy for COVID-19 | 허중연 |
| 2021 | | Korean Society of infectious diseases/national evidence-based healthcare collaborating agency recommendations for anti-SARS-CoV-2 monoclonal antibody treatment of patients with COVID-19 | 허중연 |
| 2022 | | Maternal and Neonatal Outcomes in Pregnant Women With Coronavirus Disease 2019 in Korea | 김은진 |
| 2023 | | Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study | 허중연 |
| 2021 | | Revised Korean society of infectious diseases/national evidence-based healthcarea collaborating agency guidelines on the treatment of patients with COVID-19 | 허중연 |
| 2023 | | Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis | 허중연 |
| 2022 | | Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial | 허중연 |
| 2022 | | Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network | 박래웅, 최영화 |
| 2023 | | Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity | 허중연 |
| 2022 | | Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment | 김영롱, 유진세, 허중연 |
1
